Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

During median follow-up of 76.3 months, this RCT found addition of bevacizumab to gemcitabine and cisplatin (GC) did not result in improved OS (N=506; median survival 14.5 vs 14.3 months for GC plus placebo; HR = 0.87; 95% CI, 0.72 to 1.05; P = 0.14).

Journal of Clinical Oncology